SI9620071A - Novi izoksazolinski in izoksazolni fibrinogenski receptorski antagonisti - Google Patents

Novi izoksazolinski in izoksazolni fibrinogenski receptorski antagonisti Download PDF

Info

Publication number
SI9620071A
SI9620071A SI9620071A SI9620071A SI9620071A SI 9620071 A SI9620071 A SI 9620071A SI 9620071 A SI9620071 A SI 9620071A SI 9620071 A SI9620071 A SI 9620071A SI 9620071 A SI9620071 A SI 9620071A
Authority
SI
Slovenia
Prior art keywords
alkyl
substituted
aryl
alkoxy
acetyl
Prior art date
Application number
SI9620071A
Other languages
English (en)
Slovenian (sl)
Inventor
John Wityak
Gary Avonn Cain
Douglas Guy Batt
Donald Pinto
Munir Alwan Hussain
Chu-Biao Xue
Thais Motria Sielecki-Dzurdz
Richard Eric Olson
William Frank Degrado
Shaker Ahmed Mousa
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of SI9620071A publication Critical patent/SI9620071A/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9620071A 1995-05-31 1996-05-30 Novi izoksazolinski in izoksazolni fibrinogenski receptorski antagonisti SI9620071A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/455,436 US5849736A (en) 1993-11-24 1995-05-31 Isoxazoline and isoxazole fibrinogen receptor antagonists
PCT/US1996/007692 WO1996038426A1 (en) 1995-05-31 1996-05-30 Novel isoxazoline and isoxazole fibrinogen receptor antagonists

Publications (1)

Publication Number Publication Date
SI9620071A true SI9620071A (sl) 1998-12-31

Family

ID=23808800

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9620071A SI9620071A (sl) 1995-05-31 1996-05-30 Novi izoksazolinski in izoksazolni fibrinogenski receptorski antagonisti

Country Status (26)

Country Link
US (2) US5849736A (cs)
EP (1) EP0832076B1 (cs)
JP (1) JPH11504651A (cs)
KR (1) KR19990022198A (cs)
CN (1) CN1202893A (cs)
AT (1) ATE245150T1 (cs)
AU (1) AU723577B2 (cs)
BR (1) BR9609151A (cs)
CA (1) CA2222147A1 (cs)
CZ (1) CZ374397A3 (cs)
DE (1) DE69629116T2 (cs)
EA (1) EA000924B1 (cs)
EE (1) EE9700312A (cs)
ES (1) ES2198483T3 (cs)
HU (1) HUP9900102A3 (cs)
IL (1) IL118262A (cs)
LT (1) LT4416B (cs)
LV (1) LV12046B (cs)
NZ (1) NZ309944A (cs)
PL (1) PL323835A1 (cs)
RO (1) RO117324B1 (cs)
SI (1) SI9620071A (cs)
SK (1) SK162097A3 (cs)
TW (1) TW454007B (cs)
WO (1) WO1996038426A1 (cs)
ZA (1) ZA964486B (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
AU6645998A (en) * 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
AU7958098A (en) * 1997-06-10 1998-12-30 Regents Of The University Of Minnesota Inhibitors of microbial adherence or invasion as therapeutic agents and broad-spectrum enhancers of antibiotic therapy
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
BR9810151A (pt) * 1997-06-19 2000-08-08 Du Pont Pharm Co Composto, composição farmacêutica e método para tratamento ou prevenção de uma desordem tromoboembólica
ZA988735B (en) * 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
CA2315370A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
ZA99168B (en) * 1998-01-16 2000-07-11 Du Pont Pharm Co Pharmaceutical formulations and processes for their preparation.
ES2230841T3 (es) 1998-03-27 2005-05-01 Bristol-Myers Squibb Pharma Company Pirazolinas y triazolinas disustituidas como inhibidores del factor xa.
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
AU5467699A (en) 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6583141B1 (en) 1998-10-09 2003-06-24 Janssen Pharmaceutica, N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6319937B1 (en) * 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6303609B1 (en) * 1998-11-18 2001-10-16 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
DE60003025T2 (de) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
WO2001007436A2 (en) * 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
EP1289983A2 (en) * 2000-06-15 2003-03-12 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
UY26780A1 (es) * 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
CA2450589C (en) 2001-06-08 2011-12-20 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
US20040043988A1 (en) * 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
BR0215098A (pt) * 2001-11-26 2004-12-14 Genentech Inc Composição útil para remoção de coágulos de sangue, método para a remoção de coágulos de sangue, catéter e embalagens de múltiplos compartimentos
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2004058760A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
BR0316875A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso
CA2507699A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US7576135B2 (en) * 2002-12-25 2009-08-18 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
HRP20141241T1 (hr) 2004-03-05 2015-02-13 Nissan Chemical Industries, Ltd. Spoj benzamida supstituiran izoksazolinom i sredstvo za suzbijanje štetnih organizama
WO2005094329A2 (en) * 2004-03-26 2005-10-13 Cytokine Pharmasciences, Inc. Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
ATE548359T1 (de) * 2004-06-17 2012-03-15 Infinity Discovery Inc Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern
CN101217953A (zh) * 2005-03-15 2008-07-09 加尼亚尔免疫治疗公司 具有免疫调节活性的化合物
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1932836B1 (en) 2005-09-02 2013-11-06 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
EA019879B1 (ru) 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
US8916148B2 (en) 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
AU2008261793A1 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
RU2508102C2 (ru) 2007-06-27 2014-02-27 Е.И.Дюпон Де Немур Энд Компани Способ борьбы с вредителями животных
TWI461411B (zh) 2007-08-17 2014-11-21 Du Pont 製備5-鹵烷基-4,5-二氫異唑衍生物之方法
KR20100075996A (ko) 2007-10-03 2010-07-05 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충의 방제를 위한 나프탈렌 이속사졸린 화합물
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TWI583664B (zh) 2008-04-09 2017-05-21 杜邦股份有限公司 羰基化合物及其製備方法
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20130172553A1 (en) * 2009-11-25 2013-07-04 Cpsi Stockholder Trust Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof
UA108881C2 (xx) 2010-05-27 2015-06-25 Кристалічна форма 4-$5-$3-хлор-5-(трифторметил)феніл]-4,5-дигідро-5-(трифторметил)-3-ізоксазоліл]-n-$2-оксо-2-$(2,2,2-трифторетил)аміно]етил]-1-нафталінкарбоксаміду
EP2854805B1 (en) 2012-04-17 2019-06-12 GeneOne Life Science Inc. Compounds having immunomodulator activity
WO2018089358A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
BR112019009293A2 (pt) * 2016-11-08 2019-07-30 Bristol-Myers Squibb Company pirrol amidas como inibidores de integrina alfa v
CA3042714A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Indazole derivatives as a .alpha.v integrin antagonists
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
CN111433207B (zh) 2017-11-07 2023-07-25 百时美施贵宝公司 作为αV整合素抑制剂的吡咯并吡嗪衍生物
CN112312910A (zh) * 2018-04-12 2021-02-02 莫菲克医疗股份有限公司 人整合素α4β7拮抗剂
ES3035561T3 (en) 2019-10-16 2025-09-04 Morphic Therapeutic Inc Inhibiting human integrin alpha4beta7
CN111323570B (zh) * 2020-03-25 2021-11-05 天津市宝坻区人民医院 基于血栓弹力图的阿司匹林药物抵抗检测方法
KR20240046882A (ko) 2021-08-13 2024-04-11 라픽스 테라퓨틱스, 인코포레이티드 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법
EP4509511A1 (en) 2023-08-17 2025-02-19 Bayer Aktiengesellschaft Substituted spiro-isoxazolinyl lactams, salts thereof and their use as herbicidally active substances

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2811190A1 (de) * 1978-03-15 1979-09-20 Bayer Ag Verfahren zur herstellung von 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazolinen
DE2852924A1 (de) * 1978-12-07 1980-06-26 Bayer Ag Substituierte spiro-derivate von 3- (3,5-dihalogenphenyl)-oxazolidin-2,4-dionen (thion-onen), verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
RU2097378C1 (ru) * 1991-03-26 1997-11-27 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ N-АЦИЛ- α -АМИНОКИСЛОТЫ ИЛИ ИХ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ПРОСТЫЕ ИЛИ СЛОЖНЫЕ ЭФИРЫ, АМИДЫ ИЛИ ГИДРАТЫ И КОМПОЗИЦИЯ ИНГИБИРУЮЩАЯ СВЯЗЫВАНИЕ АДГЕЗИВНЫХ ПРОТЕИНОВ С ТРОМБОЦИТАМИ И АГРЕГАЦИЮ ТРОМБОЦИТОВ
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
US5220050A (en) * 1991-05-17 1993-06-15 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4207254A1 (de) * 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1994002472A1 (en) * 1992-07-15 1994-02-03 Taisho Pharmaceutical Co., Ltd. Thiazoline derivative
US5478945A (en) * 1992-07-15 1995-12-26 Taisho Pharmaceutical Co., Ltd. Thiazoline derivatives
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US5786373A (en) * 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69327536T2 (de) * 1992-10-14 2000-07-06 Merck & Co., Inc. Fibrinogenrezeptor-antagonisten
AU675689B2 (en) * 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3173792B2 (ja) * 1993-02-22 2001-06-04 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5430043A (en) * 1993-08-24 1995-07-04 G. D. Searle & Co. Platelet aggregation inhibitors
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
AU695853B2 (en) * 1993-11-24 1998-08-27 Du Pont Pharmaceuticals Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
ES2120713T3 (es) * 1993-11-24 1998-11-01 Du Pont Merck Pharma Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.

Also Published As

Publication number Publication date
ZA964486B (en) 1997-12-01
CN1202893A (zh) 1998-12-23
RO117324B1 (ro) 2002-01-30
DE69629116D1 (de) 2003-08-21
HUP9900102A2 (hu) 1999-05-28
LV12046B (en) 1998-09-20
JPH11504651A (ja) 1999-04-27
LT4416B (lt) 1998-12-28
EP0832076B1 (en) 2003-07-16
US6114328A (en) 2000-09-05
BR9609151A (pt) 1999-06-29
HUP9900102A3 (en) 2001-11-28
SK162097A3 (en) 1999-04-13
ATE245150T1 (de) 2003-08-15
EA199700452A1 (ru) 1998-10-29
LV12046A (lv) 1998-05-20
DE69629116T2 (de) 2004-04-08
TW454007B (en) 2001-09-11
IL118262A0 (en) 1996-09-12
KR19990022198A (ko) 1999-03-25
IL118262A (en) 2003-02-12
LT97182A (en) 1998-07-27
CZ374397A3 (cs) 1998-12-16
AU6024396A (en) 1996-12-18
AU723577B2 (en) 2000-08-31
NZ309944A (en) 1999-10-28
EE9700312A (et) 1998-06-15
ES2198483T3 (es) 2004-02-01
EA000924B1 (ru) 2000-06-26
CA2222147A1 (en) 1996-12-05
US5849736A (en) 1998-12-15
EP0832076A1 (en) 1998-04-01
PL323835A1 (en) 1998-04-27
WO1996038426A1 (en) 1996-12-05

Similar Documents

Publication Publication Date Title
SI9620071A (sl) Novi izoksazolinski in izoksazolni fibrinogenski receptorski antagonisti
EP0730590B1 (en) isoxazoline and isoxazole fibrinogen receptor antagonists
US5710159A (en) Integrin receptor antagonists
CA2249733A1 (en) Spirocycle integrin inhibitors
DE69617010T2 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
US6319937B1 (en) Isoxazoline fibrinogen receptor antagonists
HK1023118A (en) Novel isoxazoline and isoxazole fibrinogen receptor antagonists
EP0922039A1 (en) Cyclic carbamates and isoxazolidines as iib/iiia antagonists